Phase
Condition
Allo-hematopoietic Stem Cell Transplant
Stem Cell Transplant
Allogeneic Hematopoietic Stem Cell Transplant
Treatment
Viral specific VST Infusion
Clinical Study ID
Ages > 4 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Recipient must be at least 21 days after stem cell infusion
Clinical status must allow tapering of steroids to 0.5mg/kg prednisone or othersteroid equivalent
Recipient must have achieved engraftment with ANC ≥ 500
Exclusion
Exclusion Criteria:
Active acute GVHD grades II-IV
Uncontrolled bacterial or fungal infection
Uncontrolled relapse of malignancy requiring treatment with chemotherapy
Infusion of ATG or alemtuzumab within 2 weeks of VST infusion
Study Design
Study Description
Connect with a study center
Akron Children's Hospital
Akron, Ohio 44308
United StatesActive - Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United StatesActive - Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio 45219
United StatesCompleted
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.